AP-IS: Lung cancer, Ablative high Precision radiotherapy and the Immune System: Evaluation of the immune-modulatory effects of stereotactic body radiation therapy (SBRT) of pulmonary lesions - L-AP-IS

niversitätsklinikum Freiburg, Klinik für Strahlenheilkunde0 个研究点目标入组 75 人开始时间: 2017年1月10日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•Primary or recurrent non-metastatic NSCLC or
•Solitary or oligometastasic pulmonary metastasis of otherwise controlled malignant
•Lesions confirmed by either histology or cytology or clear imaging signs of malignant tumors
•Patient scheduled and eligible for SBRT with curative intention
•Whole body FDG-PET scan + WB-CT or CT of chest and upper abdomen
•Written informed consent must be given according to ICH/GCP, and national/local regulations
•Adequate birth control measures during the study treatment period

•Other active or significantly bone marrow suppressing malignancy
•WHO performance status < 2
•Prior radiotherapy to chest and/or mediastinum within 3 months before the start of SBRT
•Chemotherapy and/or targeted treatment within 3 months before the start of SBRT
•Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
•Pregnancy

发起方

niversitätsklinikum Freiburg, Klinik für Strahlenheilkunde